Preview

Онкоурология

Расширенный поиск

ЛЕЧЕНИЕ БОЛЬНЫХ МЫШЕЧНО-НЕИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ ПОСЛЕ НЕУДАЧНОГО ПРИМЕНЕНИЯ ВНУТРИПУЗЫРНОЙ БЦЖ-ТЕРАПИИ

https://doi.org/10.17650/1726-9776-2010-6-3-51-56

Полный текст:

Аннотация

Неудачи БЦЖ-терапии мышечно-неинвазивного рака мочевого пузыря классифицируются как БЦЖ-рефрактерность, БЦЖ- резистентность, рецидивы после БЦЖ-терапии. У части больных отмечается непереносимость БЦЖ, в связи с чем лечение приходится прекращать. Выявляемые у пациентов БЦЖ-рефрактерность, ранние рецидивы заболевания ассоциируются с высоким риском прогрессии, высокой опухолеспецифической смертностью и являются показаниями к выполнению немедленной цистэктомии. При наличии у больных группы высокого риска дополнительных неблагоприятных прогностических факторов прогрессии заболевания следует отдать предпочтение ранней цистэктомии. Консервативное лечение больных с неудачами БЦЖ-терапии может проводиться только в рамках исследовательских программ.

Об авторе

К. М. Фигурин
ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


Список литературы

1. Babjuk M., Oosterlinck W., Sylvester R. et al. Guidelines on non-muscle invasive bladder cancer. EAU, 2009. P. 7–17.

2. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466–77.

3. Kurth K., Tunn U., Ay R. et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European organization for research and treatment of cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 1997;158(2): 378–84.

4. Lamm D.L. Diagnosis and treatment of bladder cancer. Anti-Cancer Drugs 1992;3(1):39–47.

5. Pawinski A., Bouffioux C., Sylvester R. et al. Meta-analysis of EORTC/MRC random mixed clinical trials for prophylactic treatment of Ta, T1 bladder cancer. J Urol 1996;155:492.

6. Tolley D.A., Parmar M.K.B., Grigor K.M., Lallemand G. and the Medical research council superficial bladder cancer working party. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol 1996;155(4):1233–8.

7. Böhle A., Bock P.R. Intravesical bacillus Calmette-Guer3 in versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682–7.

8. Sylvester R.J., van der Meijden A.P.M., Lamm D.L. Intravesical bacillus Calmette-Guer3 in reduces the risk of progression in patient with superficial bladder cancer: a metaanalysis of the published results of randomized clinical trials. J Urol 2002;168(5):1964–70.

9. Persad R., Lamm D., Brausi M. et al. Current approaches to the management of nonmuscle invasive bladder cancer: comparison of current guidelines and recommendations. Eur Urol Suppl 2008;7(10):637–50.

10. Van der Meijden A.P., Sylvester R.J., Oosterlinck W. et al and EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guer3 in for Ta T1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429–34.

11. Brake M., Loertzer H., Horsch R. Longterm resultsof intravesical bacillus Calmette-Guer3 in therapy for stage T1 superficial bladder cancer. Urology 2000;55:673–8.

12. Catalona W.J., Hudson M.A., Gillen D.P. et al. Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guer3 in therapy for superficial bladder cancer. J Urol 1987;137:220–4.

13. Pansadoro V., De Paula F. Intravesical bacillus Calmette-Guer3 in in the treatment of superficial transitional cell carcinoma of the bladder. J Urol 1987;138:299–301.

14. Bianco F.J., Justa D., Grignon D.J. et al. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 2004;22:290–4.

15. Lerner S.P., Tangen C.M., Sucharew H. et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 2009;27:155–9.

16. Lockyer C.R.W., Sedgwick J.E.C., Gillat D.A. Beware the BCG failures: a rewiew of one institution,s results. Eur Urol 2002;42:542–6.

17. Schrier B.P.H., Hollander M.P., van Rhijn B.W.G. et al. Prognosis of muscle invasive bladder cancer: difference between primary and progressive tumours: possible implications for therapy. Eur Urol 2004;45:292–6.

18. Skinner E.C. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol Oncol 2007;25:523–5.

19. Gattegno B. T1G3 bladder cancer: conservative management or cystectomy? Eur Urol 2004;45:399–400.

20. Herr H.W., Dalbagni G. Defining bacillus Calmette-Guer3 in refractory superficial bladder tumors. J Urol 2003;169:1706–8.

21. Herr H.W., Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166(4):1296–9.

22. Simon M.A., Nieder A.M., Manoharan M. et al. Radical cystectomy after BCG: are we waiting too long? J Urol 2005;173(4). AUA Annual Meeting,Program Abstracts. San Antonio: AUA, 2005.

23. Nieder A.M., Simon M.A., Kim S.S. et al. Radical cystectomy after bacillus Calmette-Guer3 in for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology 2006;67:737–41.

24. Herr H.W. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997;80(5):162–5.

25. Witjes A. Management of the first recurrence of T1G3 bladder cancer: does intravesical chemotherapy deserve a chance? Urol Oncol 2009;27:322–4.

26. Lamm D., Colombel M., Persad R. et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol Suppl 2008; 7(10):651–66.

27. Lee C.T., Montie J.E., Zhang Y.X. et al. Lymphovascular invasion is an independent predictor of survival in cT1 bladder cancer. J Urol 2005;173(4). AUA Annual Meeting, Program Abstracts. San Antonio: AUA, 2005. Abstr 911.

28. Denzinger S., Fritsche H.-M., Otto W. et al. Early versus deferred cystectomy for initial highrisk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladdersparing approach? Eur Urol 2008;52(1):146–52.

29. Masood S., Sriprasad S., Palmer J.H. et al. T1G3 bladder cancer – indications for early cystectomy. Int Urol Nephrol 2004;36:41–4.

30. Malavaud B. T1G3 bladder tumours: the case for radical cystectomy. Eur Urol 2004;45:406–10.

31. O'Donnell M.A., Krohn J., DeWolf W.C. Salvage intravesical therapy with interferon α-2b plus low dose Bacillus Calmette-Guer3 in is effective in patients with superficial bladder cancer in whom Bacillus Calmette-Guer3 in alone previously failed. J Urol 2001;166(4):1300–5.

32. Maymi J.L., O`Donnell M.A. Factors affecting response to BCG plus interferon in patients with urothelial carcinoma in situ. J Urol 2005;173(4). AUA Annual Meeting, Program Abstracts. San Antonio: AUA, 2005. Abstr 918.

33. Malmstrom P.U., Wijkstrom H., Lundholm C. et al. 5-year follow up of a randomized prospective study comparing mitomycin C and Bacillus Calmette-Guer3 in in patients with superficial bladder carcinoma. J Urol 1999;161(4): 1124–7.

34. Natif O., Witjes J.A., Hendricksen K. et al. Combined thermo-chemotherapy for recurrent bladder cancer after Bacillus Calmette-Guer3 in.J Urol 2009;182(4): 1313–7.

35. Van der Heijden A.G., Kiemeney L.A.,Gofrit O.N. et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46(1):65–72.

36. Серегин И.В., Самойленко В.М., Фигурин К.М. Внутрипузырное применение гемцитабина у больных поверхностным раком мочевого пузыря, резистентным к внутрипузырной иммунотерапии вакциной БЦЖ. Онкоурология 2005;(2):32–3.

37. Gontero P., Casetta G., Maso G. et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 2004;46(3):339–43.

38. Laufer M., Ramalingam S., Schoenberg M.P et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003;21(4):697–703.

39. Mohanty N.K., Nayak R.L., Vasudeva P., Arora R.P. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder – our experience. Urol Oncol 2008;26(6):616–9.

40. Barlow L.M., McKiernan J., Sawczuk I., Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. Br J Urol 2009;104(8):1098–102.

41. Waidelich R., Stepp H., Baumgartner R. et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001;165(6):1904–7.

42. Wo J.Y., Shipley W.U., Dahl D.M. et al. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? Br J Urol 2009;104(2):179–83.


Для цитирования:


Фигурин К.М. ЛЕЧЕНИЕ БОЛЬНЫХ МЫШЕЧНО-НЕИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ ПОСЛЕ НЕУДАЧНОГО ПРИМЕНЕНИЯ ВНУТРИПУЗЫРНОЙ БЦЖ-ТЕРАПИИ. Онкоурология. 2010;6(3):51-56. https://doi.org/10.17650/1726-9776-2010-6-3-51-56

For citation:


Figurin K.M. TREATMENT IN PATIENTS WITH MUSCLE NONINVASIVE CARCINOMA OF THE URINARY BLADDER AFTER UNSUCCESSFUL INTRAVESICULAR BCG THERAPY. Cancer Urology. 2010;6(3):51-56. (In Russ.) https://doi.org/10.17650/1726-9776-2010-6-3-51-56

Просмотров: 309


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)